Yükleniyor... / Loading...
This study evaluates the PARP inhibitor Olaparib in patients with advanced breast cancer carrying a BRCA1 or BRCA2 gene mutation. It included patients with measurable disease who had failed at least one prior chemotherapy. It was a Phase 2 study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Advanced breast cancer with positive BRCA1 or BRCA2 status * Failed at least one prior chemotherapy * In investigators opinion, no curative standard therapy exists * Measurable disease Exclusion Criteria: * Brain metastases * Less than 28 days since last treatment used to treat the disease * Considered a poor medical risk due to a serious uncontrolled disorder